PharmExec Blog

Filling the Rx Gap: Cost Solutions at the Point-of-Sale

Prescription abandonment—cited as one of the major cost-related issues in healthcare—has prompted numerous efforts to raise the profile of pharmacists in driving improvements in patient utilization. With a marked decline in engagement elsewhere—physician prescribers are seeing fewer sales reps and DTC spending is ebbing – more solutions providers are seeking to fill the gap, with new tools to help support pharmacists in providing effective cost solutions to patients directly at a medication’s point-of-sale.

Cost is being seen more often a key barrier that patients struggle with in determining whether to fill a prescription. A 2010 study in the Annals of Medicine cited that “prescriptions with a copayment of greater than 50$ were 4.68 times more likely to be abandoned than prescriptions without any copayment.” Patients with multiple prescriptions, and thereby multiple copayments, are the most at risk for abandoning clinically valuable therapies on cost grounds. The place where it makes the most sense to intervene and provide monetary relief to the patient, is at the point-of-sale. Hence the new focus on the pharmacist.

“Pharmacists are the last healthcare provider to interact with a patient about their medication. They are the most trusted healthcare professional when it comes to a patient’s medication,” explains Mark Bouck, President of TrialCard. This sense of trust, coupled with the frequency with which pharmacists see patients—surveys show it’s two to three times more often than physicians and non-physician prescribers—offers a unique opportunity to establish and maintain that extra rapport where other providers leave the conversation.  To facilitate this interaction, TrialCard has developed a new program, RxSaver, which gives pharmacists the opportunity to offer a sponsored copayment sharing program in the event that a patient is seeking to abandon a prescription. This ultimately increases traffic at the participating pharmacies while increasing access to branded therapies for patients, helping to foster customer loyalty in multiple ways.

Bouck notes that RxSaver, in its initial test run, saved 14.2% prescriptions from being abandoned. TrialCard touts the program as a new option for harried brand managers, who have seen budgets for promotional spend slashed at the same time regulatory headwinds are making it harder to find alternative ways to engage with those who make prescribing decisions.  TrialCard’s fresh emphasis on the pharmacist, along with the software to speed and document the options that drug companies can offer to help patients limit their exposure to the add-on costs now present in many pharmacy benefit plans,  is evidence that the battle to move the needle on low adherence rates has entered a new, hopefully more successful, phase.

This entry was posted in Strategy and tagged , , , , , , , , , , , . Bookmark the permalink. Trackbacks are closed, but you can post a comment.

3 Comments

  1. Joshua
    Posted July 17, 2013 at 2:06 pm | Permalink

    “Cost is being seen more often a key barrier that patients struggle with in determining whether to fill a prescription.”
    We have found an innovative way to deal with such costs.
    Pharmly – is a pharmaceutical bidding marketplace that allows you to source product and obtain quotes from licensed vendors FREE of charge to you. Our compliance team handles making sure the vendors are properly licensed before they submit quotes to you. Register today at: http://www.pharmly.com

  2. Posted July 18, 2013 at 10:32 am | Permalink

    An impressive discuss, I just given this onto a new colleague who was simply doing a tiny analysis about this. And he in fact bought me breakfast since i found it pertaining to him.. smile. So let me reword in which: Thnx for the handle! But yes Thnkx for investing the time to discuss this, I feel strongly about it and enjoy reading on this topic. If possible, as you grow expertise, can you mind changing your blog with an increase of details? It can be highly ideal for me. Huge thumb upwards for this blog post!
    theo http://journals.fotki.com/hope3bass/what-they-have-stated-412/entry/fgwddgwkrgsb/

  3. Posted July 18, 2013 at 10:49 am | Permalink

    In many cases, co-pay is as bad as no-pay for many people with restricted incomes. Do I eat and keep warm today or take my drugs as prescribed – perhaps I should take half the dose to make the prescription last longer? These are horrible choices to have to make.

    There is no easy way for pharma to get round this but it behoves the industry to be transparent about pricing and provide some value-added processes to benefit the patients to emcourage them to take their drugs as prescribed

Post a Comment

Your email is never published nor shared. Required fields are marked *

*
*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

  • Categories

  • Meta